Neuroscience

HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

Company Appoints Mohammad Shokoohi-Yekta to Lead Program and Industry Pioneer Lance Myers as AdvisorSANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT),…

7 months ago

Lynx.MD and Baptist Health Innovations Collaborate to Advance Medical Research and Development

Initiative enhances Baptist Health South Florida's efforts in medical innovation for advanced research and collaborative development.PALO ALTO, CA / ACCESSWIRE…

7 months ago

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

Company to review BXCL502 and other potential emerging pipeline candidates   Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and…

7 months ago

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug…

7 months ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential…

8 months ago

St. Joseph’s/Candler Fast Tracks Implementation of MEDITECH Expanse Ambulatory Across 100+ Providers

Expanse Oncology the next step toward creating a single, patient-centered EHRCANTON, Mass.--(BUSINESS WIRE)--St. Joseph’s/Candler Health System (Savannah, GA) has taken…

8 months ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose…

8 months ago

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live…

8 months ago

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment…

8 months ago

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:…

8 months ago